Inflammatory bowel disease secondary to treatment with ixekizumab in a patient with difficult-to-manage psoriasis.
Rev Esp Enferm Dig
; 2024 Feb 12.
Article
en En
| MEDLINE
| ID: mdl-38345483
ABSTRACT
Both psoriasis and inflammatory bowel disease (IBD) are immunomediated diseases. Some of their therapeutic tools are monoclonal antibodies. Ixekizumab is an interleukin-17 (IL-17) inhibitor approved for the treatment of psoriasis. Cases of IBD onset have been reported in patients treated with this drug. We present the case of a 35-year-old patient with the onset of ulcerative colitis (UC) type of IBD after starting ixekizumab treatment.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Rev Esp Enferm Dig
Asunto de la revista:
GASTROENTEROLOGIA
Año:
2024
Tipo del documento:
Article